Latest Breaking News On - Eric hughes - Page 14 : comparemela.com

Teva draws $100M from Royalty funding to bankroll long-acting schizophrenia drug

Teva draws $100M from Royalty funding to bankroll long-acting schizophrenia drug
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesRichard francisAscendis pharmaEric hughesTeva uzedyEli lillyZyprexa relprevvBlackstone life sciencesChief medical officer eric hughes

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q3 2023 Earnings Call Transcript

Operator: Hello, and welcome to the Q3 2023 Teva Pharmaceutical Industries Limited Earnings Conference Call. My name is Alex. I ll be coordinating the call today.

United statesJason gerberryBalaji prasadSven dethlefsRichard francisEric hughesCorporate social responsibility initiativeTeva pharmaceutical industries ltdTeva pharmaceutical industries limitedAbnormal involuntary movement scaleSpecialty pharma equity researchTeva pharmaceutical industries limited earnings conference callCall transcript novemberEran meirChief medical officerEli kalif

Teva Pharmaceutical Industries (TEVA) Q3 2023 Earnings Call Transcript

TEVA earnings call for the period ending September 30, 2023.

United statesDavid amsellem piper sandlerGlen santangeloAmerica merrill lynchBalaji prasad barclaysRichard francisBalaji prasadEric hughesSven dethlefsJason gerberryPiper sandlerGoldman sachsDavid amsellemGlen santangelo jefferiesChris schottTeva pharmaceutical industries

Study Finds That Long-Acting Schizophrenia Treatment Prolongs Time to Impending Relapse

These results were instrumental in securing the FDA approval of the drug for the treatment of schizophrenia in adults in April 2023.

New yorkUnited statesEric hughesChristoph correllTeva pharmaceuticalsZucker school of medicine at hofstra northwellUs food drug administrationRisperidone subcutaneous extended releaseAfrican americanDrug administrationZucker school

UZEDY (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

02.11.2023 - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy and safety findings from the phase 3 Risperidone Subcutaneous Extended-Release (RISE) study in The .

United statesEric hughesTeva neuroscience incMental health services administrationTeva pharmaceutical industries ltdTeva pharmaceutical industries stockNational pregnancy registry for atypical antipsychoticsExecutive vice presidentChief medical officerAfrican americanThelancet psychiatryRisperidone subcutaneous extended releaseAdverse reactionsMalignant syndromeMotor impairmentNational pregnancy registry